Hostname: page-component-7b7567c8c-7pwfn Total loading time: 0 Render date: 2026-11-14T14:57:43.544Z Has data issue: false hasContentIssue false
  • English
  • Français

Changing times: The impact of gram-negative breakpoint changes over the previous decade

Published online by Cambridge University Press:  07 October 2022

Wes M. Johnson,
Justin A. Clark,
Katherine OlneyOpen the ORCID record for Katherine Olney[Opens in a new window],
Donna R. Burgess and
David S. Burgess
Wes M. Johnson
Affiliation:
University of Kentucky Chandler Medical Center, Lexington, Kentucky
Justin A. Clark
Affiliation:
University of Kentucky College of Pharmacy, Lexington, Kentucky
Katherine Olney
Affiliation:
University of Kentucky Chandler Medical Center, Lexington, Kentucky
Donna R. Burgess
Affiliation:
University of Kentucky Chandler Medical Center, Lexington, KentuckyUniversity of Kentucky College of Pharmacy, Lexington, Kentucky
David S. Burgess*
Affiliation:
University of Kentucky College of Pharmacy, Lexington, Kentucky
*
Author for correspondence: David S. Burgess, University of Kentucky College of Pharmacy, 789 S Limestone Suite 292, Lexington, KY 40508. E-mail: david.burgess@uky.edu

Abstract

We assessed breakpoint changes of 13,101 Enterobacterales and Pseudomonas aeruginosa isolates from the past decade. All β-lactams and fluoroquinolones demonstrated decreased susceptibilities following breakpoint changes. Enterobacter cloacae experienced the largest average decrease in susceptibility amongst the Enterobacterales at 5.3% and P. aeruginosa experienced an average decrease in susceptibility of 9.3%.

Information

Type
Concise Communication
Information
Antimicrobial Stewardship & Healthcare Epidemiology , Volume 2 , Issue 1 , 2022, e165
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

The Clinical and Laboratory Standards Institute (CLSI) is a governing body responsible for establishing minimum inhibitory concentration (MIC) breakpoints. Over the past decade, multiple changes to MIC breakpoints have occurred for both Enterobacterales and Pseudomonas aeruginosa. As noted by the CLSI subcommittee on antimicrobial susceptibility testing, a microorganism’s susceptibility to an antimicrobial agent may decrease over time, thus warranting the refinement of MIC breakpoints. Reference Weinstein and Lewis1 Additionally, the new breakpoints were made to better fit MIC distribution patterns emerging in clinical practice. Reference Ambrose, Bhavnani and Andes2

Individual breakpoint changes can be found both on the CLSI website 3 and summarized by Humphries et al. Reference Humphries, Abbott and Hindler4 These changes made by CLSI directly affect the susceptibility of antibiotics. Specifically, susceptibilities of β-lactams and fluoroquinolones are of particular concern due to their common use within the inpatient setting. Reference Amaha, Berhe and Kaushik5

Questions remain regarding the quantitative effect of breakpoint changes on institutional susceptibilities. One study demonstrated a decrease in ciprofloxacin susceptibilities of 5% for Enterobacterales Reference Shealy, Brigmon, Justo, Bookstaver, Kohn and Al-Hasan6 and another demonstrated increases in institutional resistance of 6% for Escherichia coli and Enterobacter cloacae. Reference Hombach, Bloemberg and Böttger7 As bacteria continue to adapt, we must update breakpoints accordingly, otherwise we risk the provision of suboptimal treatment. In this study, we have described the impact of CLSI breakpoint changes on gram-negative organism susceptibilities in the last decade at our academic medical center.

Methods

This single-center retrospective study was conducted at the University of Kentucky Chandler Medical Center. We collected consecutive nonduplicate clinical isolates of Enterobacter cloacae, Escherichia coli, Klebsiella aerogenes, K. oxytoca, K. pneumoniae, and Pseudomonas aeruginosa between the years 2010 and 2019. We assessed aztreonam, cefepime, ceftazidime, ceftriaxone, ertapenem, and meropenem for the Enterobacterales. Fluoroquinolones were not evaluated because automated panels were unable to determine low enough MICs. We assessed ciprofloxacin, levofloxacin, meropenem and piperacillin-tazobactam for P. aeruginosa. The institutional isolates and their respective MICs were obtained from the institutional antibiogram data set. This data set also stratifies isolates that come from specific intensive care units (ICUs) including the cardiovascular ICU (CVICU), the medical ICU (MICU), and the neurosurgical ICU (NSICU).

Susceptibilities were assessed based upon historic CLSI breakpoints in 2010 as well as the current CLSI breakpoints from the most recent CLSI MIC breakpoints, the 29th edition of document M100, published in 2019. MICs were determined using automated panels in BD Phoenix software (Becton-Dickinson, Franklin Lakes, MJ). The genus and species of isolates were determined through use of matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF). Additionally, if further susceptibility testing was warranted, then an E-test was performed.

Susceptibility differences were calculated by subtracting the new susceptibilities from the old susceptibilities. Statistical analysis was performed utilizing the McNemar test to compare previous susceptibilities to current susceptibilities. P < 0.05, was considered statistically significant.

Results

In total, 13,101 clinical isolates were collected over the 10-year period. Of these isolates, 10,003 were Enterobacterales isolates and 3,098 were P. aeruginosa isolates. The Enterobacterales group consisted of 5,273 E. coli, 1,237. E. cloacae, 471 K. aerogenes, 610 K. oxytoca, and 2,412 K. pneumoniae isolates. Table 1 describes the susceptibility changes for Enterobacterales at Chandler Hospital and the ICUs. At Chandler Hospital, E. cloacae experienced the largest average change in susceptibility for all antibiotics at 5.3%, followed by K. aerogenes at 3.3%, E. coli at 2.1%, K. pneumoniae at 1.9%, and K. oxytoca at 1.8%. Table 1 also demonstrates that each organism at Chandler Hospital has at least 1 antibiotic with a statistically significant decrease in susceptibility, with E. coli and E. cloacae experiencing statistically significant changes for all antibiotics. Table 2 describes the susceptibility changes for P. aeruginosa. At Chandler Hospital, there was an average change in susceptibility of 9.3% for P. aeruginosa, with piperacillin-tazobactam demonstrating a 15.4% decrease in susceptibility. All drugs assessed with P. aeruginosa had a statistically significant reduction in susceptibilities (Table 2). Results from the ICU follow a similar trend as Chandler Hospital, but with a smaller number of isolates (Tables 1 and 2).

Table 1.

Changes in Rates of Susceptibility by Organism for Enterobacterales. Changes in susceptibilities are listed for Chandler Hospital, cardiovascular ICU, medical IDU, and the neurosurgical ICU. The individual changes are listed, along with the average. ATM aztreonam, CAZ ceftazidime, CEF cefepime, CRO ceftriaxone, ETP Ertapenem, MEM meropenemtableta,b

Note. ATM, aztreonam; CAZ, ceftazidime; CEF, cefepime; CRO, ceftriaxone; ETP, ertapenem; MEM, meropenem; ICU, intensive care unit.

a Changes in susceptibilities are listed for Chandler Hospital, cardiovascular ICU, medical IDU, and the neurosurgical ICU.

b The individual changes are listed, along with the average.

Table 2.

Changes in Rates of Susceptibility by Organism for P. aeruginosa. Changes in susceptibilities are listed for Chandler Hospital, cardiovascular ICU, medical IDU, and the neurosurgical ICU. The individual changes are listed, along with the average. ABX antibiotic, CPX ciprofloxacin, LVX levofloxacin, MEM meropenem, TZP piperacillin-tazobactama,b

Note. ABX, antibiotic; CPX, ciprofloxacin; LVX, levofloxacin; MEM, meropenem; TZP piperacillin-tazobactam; ICU, intensive care unit.

a Changes in susceptibilities are listed for Chandler Hospital, cardiovascular ICU, medical ICU, and the neurosurgical ICU.

b The individual changes are listed, along with the average.

Discussion

In this study, we have demonstrated decreased institutional susceptibilities for gram-negative pathogens following the implementation of updated CLSI breakpoints. In this study, both Enterobacterales and P. aeruginosa susceptibilities decreased institution-wide and in the various ICUs.

Our findings may not align with other institutions due to differing local susceptibilities. Shealy et al Reference Shealy, Brigmon, Justo, Bookstaver, Kohn and Al-Hasan6 assessed the effects of the MIC breakpoint changes to fluoroquinolone susceptibilities. Their findings demonstrated a decrease in susceptibility of levofloxacin to P. aeruginosa by 8% after the implementation of updated MIC breakpoint, which is in line with our findings. However, Shealy et al Reference Shealy, Brigmon, Justo, Bookstaver, Kohn and Al-Hasan6 reported more favorable susceptibilities for levofloxacin, with 89% of P. aeruginosa isolates susceptible initially. Within our institution, this rate was only 63%.

The decreased susceptibilities make it clear that microbiology laboratories should accept new MIC breakpoints. However, one study assessed the uptake of current CLSI breakpoints by microbiology laboratories in California and found that ∼1 in 3 labs were utilizing out-of-date breakpoints. Reference Humphries, Hindler and Epson8 This finding may stem from the fact that many laboratories will take at least a year to implement new breakpoints. Reference Humphries, Abbott and Hindler4 This delay in the uptake of breakpoint changes stems from antimicrobial susceptibility testing manufacturers being required to follow the breakpoints set by the Food and Drug Administration (FDA), who will accept CLSI breakpoint recommendations after an extensive review process. Reference Humphries, Abbott and Hindler4

Although our study has demonstrated decreased susceptibilities, there is no correlation with clinical outcomes. Another study assessed clinical outcomes by determining mortality associated with previous and current levofloxacin breakpoints with Enterobacterales. The outdated levofloxacin MIC was a predictor of 30-day mortality, with an odds ratio of 6.05. Additionally, the outdated MIC was associated with the emergence of resistance, 25% versus 7.5%. Reference Huang, Wang and Lu9

In conclusion, changes in breakpoints had a significant impact on the susceptibility of all antimicrobials for P. aeruginosa at our institution, both hospital-wide and in intensive care units. Although the impact was less for Enterobacterales isolates, ertapenem, ceftriaxone, and cefepime demonstrated significant susceptibility changes. Understanding and evaluating the impact of the breakpoint changes is of paramount importance. Institutions should ensure that their breakpoints are up to date to allow for the most optimized treatment.

Acknowledgments

Financial support

No financial support was provided relevant to this article.

Conflicts of interest

All authors report no conflicts of interest relevant to this article.

References

Weinstein, MP, Lewis, JS. The Clinical and Laboratory Standards Institute Subcommittee on Antimicrobial Susceptibility Testing: background, organization, functions, and processes. J. Clin. Microbiol 2020;58;e01864-19.CrossRefGoogle ScholarPubMed
Ambrose, PG, Bhavnani, SM, Andes, DR et al. Old in vitro antimicrobial breakpoints are misleading stewardship efforts, delaying adoption of innovative therapies, and harming patients. Open Forum Infect Dis 2020;7:ofaa084.CrossRefGoogle ScholarPubMed
Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, 29 th edition, CLSI supplement M100. Pittsburgh, PA: CLSI; 2019.Google Scholar
Humphries, RM, Abbott, AN, Hindler, JA. Understanding and addressing CLSI breakpoint revisions: a primer for clinical laboratories. J Clin Microbiol 2019;57:e00203–19.CrossRefGoogle ScholarPubMed
Amaha, ND, Berhe, YH, Kaushik, A. Assessment of inpatient antibiotic use in Halibet National Referral Hospital using WHO indicators: a retrospective study. BMC Res Notes 2018;11:904.CrossRefGoogle ScholarPubMed
Shealy, SC, Brigmon, MM, Justo, JA, Bookstaver, PB, Kohn, J, Al-Hasan, MN. Impact of reappraisal of fluoroquinolone minimum inhibitory concentration susceptibility breakpoints in gram-negative bloodstream isolates. Antibiotics (Basel) 2020;9:189.CrossRefGoogle ScholarPubMed
Hombach, M, Bloemberg, GV, Böttger, EC. Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of gram-negative bacilli. J Antimicrob Chemother 2012;67:622–632.CrossRefGoogle ScholarPubMed
Humphries, RM, Hindler, JA, Epson, E, et al. Carbapenem-resistant Enterobacteriaceae detection practices in California: what are we missing? Clin Infect Dis 2018;66:1061–1067.CrossRefGoogle ScholarPubMed
Huang, H-Y, Wang, C-F, Lu, P-L, et al. Clinical impact of the revised 2019 CLSI levofloxacin breakpoints in patients with Enterobacterales bacteremia. Antimicrob Agents Chemother 2021;65:e00074–21.CrossRefGoogle ScholarPubMed
Figure 0

Table 1.Changes in Rates of Susceptibility by Organism for Enterobacterales. Changes in susceptibilities are listed for Chandler Hospital, cardiovascular ICU, medical IDU, and the neurosurgical ICU. The individual changes are listed, along with the average. ATM aztreonam, CAZ ceftazidime, CEF cefepime, CRO ceftriaxone, ETP Ertapenem, MEM meropenemtableta,b

Figure 1

Table 2.Changes in Rates of Susceptibility by Organism for P. aeruginosa. Changes in susceptibilities are listed for Chandler Hospital, cardiovascular ICU, medical IDU, and the neurosurgical ICU. The individual changes are listed, along with the average. ABX antibiotic, CPX ciprofloxacin, LVX levofloxacin, MEM meropenem, TZP piperacillin-tazobactama,b